ReviewJournal of human hypertension2021
Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction.
Review in Journal of human hypertension, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Article
- Efficacy and Safety of Finerenone Combined with Dapagliflozin in the Treatment of Non-Diabetic Chronic Kidney Disease: A Single-Center Retrospective Study.Drug design, development and therapy · 2026Article
- Post hoc comparison of the intrarenal and circulating renin-angiotensin(-aldosterone) systems in cats with ischemia-induced chronic kidney disease.Physiological reports · 2025Article
- The global burden of chronic kidney disease attributable to high sodium intake: a comprehensive analysis of trends from 1990 to 2021 and burden prediction to 2040.Frontiers in nephrology · 2025Article
- Hypertension: A Continuing Public Healthcare Issue.International journal of molecular sciences · 2024Review
- Rediscovery of the implication of albuminuria in heart failure: emerging classic index for cardiorenal interaction.ESC heart failure · 2024Review
- Collecting Duct Pro(Renin) Receptor Contributes to Unilateral Ureteral Obstruction-Induced Kidney Injury via Activation of the Intrarenal RAS.Hypertension (Dallas, Tex. : 1979) · 2024Article
- Young-onset type 2 diabetes mellitus enhances proteinuria, but not glomerular filtration rate decline: A Japanese cohort study.Journal of diabetes investigation · 2024Article
- Research Progress of Drug Delivery Systems Targeting the Kidneys.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Use of corticosteroids in Norwegian patients with immunoglobulin a nephropathy progressing to end-stage kidney disease: a retrospective cohort study.BMC nephrology · 2024Article
- Aldosterone's impact on kidney health: exploring the benefits of mineralocorticoid receptor antagonists for renal protection.American journal of translational research · 2024Review
- Pathogenesis of Chronic Kidney Disease Is Closely Bound up with Alzheimer's Disease, Especially via the Renin-Angiotensin System.Journal of clinical medicine · 2023Review
- Progression of chronic kidney disease among black patients attending a tertiary hospital in Johannesburg, South Africa.PloS one · 2023Article
- A comparative study assessing the incidence and degree of hyperkalemia in patients on angiotensin-converting enzyme inhibitors versus angiotensin-receptor blockers.Journal of human hypertension · 2022Article
- Renin-angiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease.Clinical kidney journal · 2022Review
- Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges.International journal of nephrology and renovascular disease · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Management of hypertension and albuminuria are considered among the primary goals of treatment to slow the progression of chronic kidney disease (CKD). Renin-angiotensin system (RAS) blockers, i.e., angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are the main drugs to achieve these goals. Seminal studies have showed that RAS blockers present significant renoprotective effects in CKD patients with very high albuminuria. In post hoc analyses of such trials, these renoprotective effects appeared more robust in patients with more advanced CKD. However, randomized trials specifically addressing whether RAS blockers should be initiated or maintained in patients with advanced CKD are scarce and do not include subjects with normoalbuminuria, thus, many clinicians are unconvinced for the beneficial effects of RAS blockade in these patients. Further, the fear of hyperkalemia or acute renal decline is another factor due to which RAS blockers are usually underprescribed and are easily discontinued in patients with more advanced CKD; i.e., those in Stages 4 and 5. This review summarizes evidence from the literature regarding the use of RAS blockers in patients with advanced CKD.
Indexed as
Identifiers
33654237What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.